Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial.

Author: CasaliCarlo, CoarelliGiulia, FerraldeschiMichela, FrontaliMarina, LeonardiLuca, MarcotulliChristian, OrziFrancesco, PetrucciAntonio, PiccoloFrancesca, PonzelliFederica, RistoriGiovanni, RomanoSilvia, SalvettiMarco, SpadaroMaria, VanacoreNicola, VulpianiMaria Chiara

Paper Details 
Original Abstract of the Article :
BACKGROUND: Our previous study in patients with cerebellar ataxias of different causes showed significant benefit of riluzole after 8 weeks. We aimed to confirm these results in patients with spinocerebellar ataxia or Friedreich's ataxia in a 1-year trial. METHODS: Patients with spinocerebellar ata...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1016/S1474-4422(15)00201-X

データ提供:米国国立医学図書館(NLM)

Riluzole: A Potential Oasis in the Desert of Cerebellar Ataxia

Cerebellar ataxia, a condition that affects balance and coordination, is a debilitating condition that can make even simple tasks feel like trekking across a vast desert. This study explores the potential of riluzole, a medication used for treating amyotrophic lateral sclerosis, to offer a new path for these patients. The study, which involved patients with spinocerebellar ataxia or Friedreich's ataxia, was a randomized, double-blind, placebo-controlled trial that lasted for one year. The primary endpoint was the proportion of patients who showed improvement in their Scale for the Assessment and Rating of Ataxia (SARA) scores. The results revealed that riluzole led to a significantly higher proportion of patients experiencing improvement in their SARA scores compared to the placebo group.

Hope on the Horizon for Ataxia Patients

This research offers hope for those struggling with cerebellar ataxia. The findings suggest that riluzole could potentially be a valuable treatment option, providing a path toward improved balance and coordination. The study reported that 50% of patients in the riluzole group showed improvement in their SARA scores, while only 11% of those in the placebo group experienced improvement. This data suggests that riluzole may offer a significant advantage for those seeking relief from the challenges of cerebellar ataxia.

Navigating the Desert of Ataxia

While this study offers a glimmer of hope for the treatment of cerebellar ataxia, further research is needed to solidify the benefits of riluzole and guide its implementation in clinical practice. It's important to remember that the desert of ataxia can be a challenging journey, but with continued research and the development of new treatment options, we can hope to find oases of relief for those affected by this condition.

Dr. Camel's Conclusion

This study represents a significant step in the ongoing quest for effective treatments for cerebellar ataxia. While more research is needed, the potential benefits of riluzole are promising. It's important to stay hopeful as we continue to explore new pathways for relief, navigating the vast desert of medical research with determination. We can hope for a day when the challenges of ataxia become a little easier to bear, and the journey towards better health becomes a little less daunting.

Date :
  1. Date Completed 2015-12-22
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

26321318

DOI: Digital Object Identifier

10.1016/S1474-4422(15)00201-X

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.